HT
JAZZ icon

Headlands Technologies’s Jazz Pharmaceuticals JAZZ Stock Holding History

Headlands Technologies’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,846
Closed -$484K – 848
2025
Q4 		$484K Buy
+2,846
New +$436K 0.04% 403
2025
Q3 		– Sell
-3,115
Closed -$331K – 963
2025
Q2 		$331K Buy
+3,115
New +$338K 0.04% 388
2024
Q3 		– Sell
-9,607
Closed -$1.03M – 1363
2024
Q2 		$1.03M Buy
9,607
+4,714
+96% +$518K 0.11% 166
2024
Q1 		$589K Buy
+4,893
New +$599K 0.14% 171
2023
Q4 		– Sell
-601
Closed -$77.8K – 1121
2023
Q3 		$77.8K Buy
+601
New +$80.1K 0.04% 358

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Headlands Technologies's JAZZ Position: Q1 2026 in Review

Headlands Technologies sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 2,846 shares — an estimated $484K sold.

Headlands Technologies first reported a position in JAZZ in Q3 2023 and held it in 5 quarters. The position peaked at $1.03M in Q2 2024. 576 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Headlands Technologies reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Headlands Technologies sold 2,846 Jazz Pharmaceuticals shares in Q1 2026, an estimated $484K.
  • Headlands Technologies first reported a position in Jazz Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • Headlands Technologies's Jazz Pharmaceuticals position peaked at $1.03M in Q2 2024.
  • 576 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.